☆ 4.6 Letter

Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease

BRITISH JOURNAL OF HAEMATOLOGY (2011)

Journal

BRITISH JOURNAL OF HAEMATOLOGY

Volume 155, Issue 5, Pages 632-634

Publisher

WILEY

DOI: 10.1111/j.1365-2141.2011.08754.x

Keywords

myeloma; bendamustine; renal failure

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM

Friederike Bachmann, Martin Schreder, Monika Engelhardt, Christian Langer, Denise Wolleschak, Lars Olof Muegge, Heinz Duerk, Kerstin Schaefer-Eckart, Igor Wolfgang Blau, Martin Gramatzki, Peter Liebisch, Matthias Grube, Ivana Metzler, Florian Bassermann, Bernd Metzner, Christoph Roellig, Bernd Hertenstein, Cyrus Khandanpour, Tobias Dechow, Holger Hebart, Wolfram Jung, Sebastian Theurich, Georg Maschmeyer, Hans Salwender, Georg Hess, Max Bittrich, Leo Rasche, Annamaria Brioli, Kai-Uwe Eckardt, Christian Straka, Swantje Held, Hermann Einsele, Stefan Knop

Summary: Renal insufficiency is common in newly diagnosed multiple myeloma, and it can be caused by the disease itself, medical interventions, or infections. Quick disease control with effective therapy can help improve renal function. Different three-drug regimens for initial myeloma treatment had a positive impact on kidney function, but some patients may experience worsening renal function following induction therapy.

CANCERS (2021)

Add to Collection

Article Oncology

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network

Francesca Gay, Andreas Guenther, Massimo Offidani, Monika Engelhardt, Marco Salvini, Vittorio Montefusco, Francesca Patriarca, Sara Aquino, Wolfram Poenisch, Stefano Spada, Natalie Schub, Silvia Gentili, Ralph Waesch, Paolo Corradini, Christian Straka, Antonio Palumbo, Hermann Einsele, Mario Boccadoro, Pieter Sonneveld, Martin Gramatzki

Summary: The study evaluated the combination therapy with carfilzomib, bendamustine, and dexamethasone in patients with relapsed/refractory multiple myeloma. The results showed a clinical benefit rate of 93% and a median overall survival of 30.4 months, indicating that this treatment option is effective for heavily pretreated patients.

CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group

Norbert Grzasko, Grzegorz Charlinski, Marta Morawska, Pawel Kicinski, Anna Waszczuk-Gajda, Joanna Drozd-Sokolowska, Edyta Subocz, Danuta Blonska, Malgorzata Razny, Agnieszka Druzd-Sitek, Jadwiga Holojda, Alina Swiderska, Lidia Usnarska-Zubkiewicz, Anna Masternak, Krzysztof Giannopoulos

Summary: This study suggests that bendamustine may be an effective treatment for patients with refractory/relapsed multiple myeloma. Three-drug regimens containing bendamustine, steroids, and novel agents produced better outcomes and had acceptable toxicity. The efficacy of bendamustine combined with steroids was limited.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Hematology

Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the real world

Hira S. Mian, Mark A. Fiala, Larysa Sanchez, Ravi Vij, Tanya M. Wildes

Summary: Renal failure occurred in up to 22% of patients with multiple myeloma treated with Carfilzomib, with increasing age, pre-existing heart failure, and chronic kidney disease as risk factors. Further studies are needed to understand the exact cause and develop strategies to mitigate the risk.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial

Sudhir Kumar, Atul Sharma, Prabhat Singh Malik, Ajay Gogia, Neha Pathak, Ranjit Kumar Sahoo, Ritu Gupta, Chandra Prakash Prasad, Lalit Kumar

Summary: This study evaluated the role of bendamustine, pomalidomide, and dexamethasone combination therapy in patients with resistant/refractory multiple myeloma. The results showed an overall response rate of 57.6% and median progression-free survival of 6.2 months. The combination therapy was well-tolerated with manageable toxicity.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Meletios A. Dimopoulos, Xavier Leleu, Philippe Moreau, Paul G. Richardson, Anna Marina Liberati, Simon J. Harrison, H. Miles Prince, Enrique M. Ocio, Sylvie Assadourian, Frank Campana, Laure Malinge, Dorothee Semiond, Helgi van de Velde, Kwee Yong

Summary: The ICARIA-MM study found that in patients with renal impairment and relapsed/refractory multiple myeloma, the Isa-Pd treatment regimen improved progression-free survival, overall response rate, and complete renal response rates compared to Pd.

LEUKEMIA (2021)

Add to Collection

Article Hematology

Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Societe Francophone de Greffe de Moelle-Therapie Cellulaire observational study

Laurent Garderet, Hafida Ouldjeriouat, Mohamed-Amine Bekadja, Elisabeth Daguenet, Noemie Bigot, Laure Vincent, Damien Roos-Weil, Marguerite Vignon, Souhila Ikhlef, Julie Abraham, Martine Escoffre-Barbe, Bruno Lioure, Redhouane Ahmed Nacer, Ingrid Lafon, Clara Mariette, Lionel Karlin, Pierre Morel, Lila Gilis, Emanuelle Le Ray, Anaise Blouet, Stephanie Nguyen Quoc, Jean Jacques Boffa, Pierre Ronco, Jerome Lambert, Jerome Cornillon

Summary: This study investigated the safety and efficacy of high-dose melphalan followed by autologous haematopoietic stem cell transplantation in patients with renal insufficiency. The results showed that there was only one death within 100 days post-transplant, and the patients showed improved haematological response and renal function.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study

Danilo De Novellis, Raffaele Fontana, Angela Carobene, Bianca Serio, Idalucia Ferrara, Maria Carmen Martorelli, Laura Mettivier, Roberto Guariglia, Serena Luponio, Immacolata Ruggiero, Matteo D'Addona, Tiziana Di Leo, Valentina Giudice, Carmine Selleri

Summary: The study found that the serum free light-chain (FLC) ratio in plasma cell disorder patients is associated with disease burden and renal damage. This finding is important for early identification of renal damage and minimizing the risk of late renal failure.

BIOMEDICINES (2022)

Add to Collection

Letter Medicine, General & Internal

Empagliflozin and Major Renal Outcomes in Heart Failure

Milton Packer, Javed Butler, Faiez Zannad, Stuart J. Pocock, Gerasimos Filippatos, Joao P. Ferreira, Martina Brueckmann, Waheed Jamal, Cordula Zeller, Christoph Wanner, Stefan D. Anker

Summary: Empagliflozin had different effects on renal outcomes in heart failure patients between two trials, with major adverse renal outcomes occurring in 2.8% of patients who received the drug and 3.5% of those who received a placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Oncology

Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019

Ghulam Rehman Mohyuddin, Kelly Koehn, Leyla Shune, Muhammad Aziz, Al-Ola Abdallah, Brian McClune, Siddhartha Ganguly, Joseph McGuirk, Suman Kambhampati

Summary: The study found that there is inconsistency in reporting and enrollment of patients with renal insufficiency in multiple myeloma randomized clinical trials, and that this group of patients had a higher risk of disease progression or death.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Endocrinology & Metabolism

Multiple myeloma following bone metastasis of renal cell carcinoma: a case report

Hong Yu, Shengnan Zhang, Xiaohui Feng, Feng Gao

Summary: It is difficult to differentiate between MM and bone metastatic tumor based on imaging alone, especially when there are concurrent bone lesions. A comprehensive evaluation combining functional procedures, clinical laboratory tests, and histopathology is needed to avoid missed diagnosis.

FRONTIERS IN ENDOCRINOLOGY (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Optimising cardiovascular care of patients with multiple myeloma

Marta Fontes Oliveira, Willeke R. Naaktgeboren, Alina Hua, Arjun K. Ghosh, Heather Oakervee, Simon Hallam, Charlotte Manisty

Summary: Multiple myeloma is a common hematological malignancy with cardiovascular events impacting survival rates. Management of comorbidities and routine cardiovascular surveillance are essential in improving clinical outcomes for MM patients.

HEART (2021)

Add to Collection

Article Biophysics

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial

Sarah Farag, Ulrike Bacher, Barbara Jeker, Myriam Legros, Gaelle Rhyner, Jean-Marc Luthi, Julian Schardt, Thilo Zander, Michael Daskalakis, Behrouz Mansouri, Chantal Manz, Thomas Pabst

Summary: This study compared the efficacy of combining bendamustine with melphalan to melphalan alone in the treatment of multiple myeloma. The results showed that the combination therapy significantly improved the complete remission rate and stringent complete remission rate/response rate in patients.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Peripheral Vascular Disease

Renal, Cardiac, and Autonomic Effects of Catheter-Based Renal Denervation in Ovine Heart Failure

Lindsea C. Booth, R. Anethra U. de Silva, Roberto B. Pontes, Song T. Yao, Sally G. Hood, Yugeesh R. Lankadeva, Junko Kosaka, Nina Eikelis, Gavin W. Lambert, Markus P. Schlaich, Clive N. May

Summary: Clinical studies suggest that renal denervation (RDN) has beneficial effects on the autonomic control of the heart in heart failure, with experimental evidence showing improvements in sodium handling and clearance. In sheep with established heart failure, catheter-based RDN led to decreased heart rate, increased parasympathetic control, and improved kidney function, indicating potential benefits for both the heart and kidneys in heart failure.

HYPERTENSION (2021)

Add to Collection

Review Pharmacology & Pharmacy

A comprehensive review of acute cardio-renal syndrome: need for novel biomarkers

Abhi Dutta, Shubham Saha, Ajay Bahl, Anupam Mittal, Trayambak Basak

Summary: Cardiorenal syndrome is a broad spectrum disorder affecting the heart and kidneys. India has a high burden of acute cardiorenal syndrome, with 46.1% of patients diagnosed in India. Acute cardiorenal syndrome involves sudden kidney deterioration in acute heart failure patients. The pathophysiology includes hyperactivation of the sympathetic nervous system and the renin-angiotensin-aldosterone system. Complications increase the risk of mortality, making it a global healthcare burden. Current biomarkers have limitations in early detection, highlighting the need for novel proteomic biomarkers to prevent progression.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Article Hematology

A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis

Sriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, Sajitha Sachchithanantham, Rakesh Popat, Helen Lachmann, Neil Rabin, Karthik Ramasamy, Stephen Hawkins, Charalampia Kyriakou, Julian Gillmore, Kwee Yong, Philip Hawkins, Graham Jackson, Guy Pratt, Ashutosh D. Wechalekar

Summary: This study found that depth of response is critical in the prognosis of AL amyloidosis. By analyzing patients' baseline characteristics and 1-month response, those unlikely to improve treatment response can be identified. It is recommended that patients with a significant difference in involved and uninvolved serum free light chains at diagnosis and no response at 1 month switch treatment early.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma

Parvathi Sudha, Aarif Ahsan, Cody Ashby, Tasneem Kausar, Akhil Khera, Mohammad H. Kazeroun, Chih-Chao Hsu, Lin Wang, Evelyn Fitzsimons, Outi Salminen, Patrick Blaney, Magdalena Czader, Jonathan Williams, Mohammad I. Abu Zaid, Naser Ansari-Pour, Kwee L. Yong, Frits van Rhee, William E. Pierceall, Gareth J. Morgan, Erin Flynt, Sara Gooding, Rafat Abonour, Karthi Ramasamy, Anjan Thakurta, Brian A. Walker

Summary: We designed and validated a comprehensive targeted sequencing panel for multiple myeloma, which can identify common genomic abnormalities in a single assay. The performance of this panel is comparable or superior to current standard methods. This cost-effective and comprehensive molecular panel can be used to guide diagnosis and treatment, and assist risk stratification for patients with multiple myeloma.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Letter Hematology

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients

Faouzi Djebbari, Alexandros Rampotas, Grant Vallance, Fotios Panitsas, Nanda Basker, Gina Sangha, Beena Salhan, Farheen Karim, Firas Al-Kaisi, Amy Gudger, Loretta Ngu, Matt Poynton, Ho Pui Jeff Lam, Lowri Morgan, Laura Yang, Jennifer Young, Mairi Walker, Ismini Tsagkaraki, Laura Anderson, Saleena Rani Chauhan, Rebecca Maddams, Richard Soutar, Margarita Triantafillou, Steve Prideaux, Abubaker Obeidalla, Toby A. Eyre, Ceri Bygrave, Jaimal Kothari, Supratik Basu, Karthik Ramasamy

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

Hans C. Lee, Karthik Ramasamy, Katja Weisel, Rafat Abonour, James W. Hardin, Robert M. Rifkin, Sikander Ailawadhi, Howard R. Terebelo, Brian G. M. Durie, Derek Tang, Prashant Joshi, Liang Liu, Ying-Ming Jou, Min Che, Gabriela Hernandez, Mohit Narang, Kathleen Toomey, Cristina Gasparetto, Lynne I. Wagner, Sundar Jagannath

Summary: This study evaluated the treatment patterns, survival, quality of life, and healthcare resource use among patients with triple-class refractory multiple myeloma (TCR MM) in US clinical practice. The findings highlight the substantial burden of TCR MM and the need for more effective treatment options.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Article Hematology

Monoclonal gammopathy of increasing significance: time to screen?

Lucia Y. Chen, Mark Drayson, Christopher Bunce, Karthik Ramasamy

Summary: Monoclonal gammopathy (MG) needs to be reassessed in terms of management and screening in clinical practice. The contribution of MG to disease states other than malignant progression is often unclear. This can lead to under recognition of the organ dysfunction that can occur with MGCS.

HAEMATOLOGICA (2023)

Add to Collection

Article Oncology

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Keiji Kurata, Anna-James Bott, Mark A. Tye, Leona Yamamoto, Mehmet K. Samur, Yu-Tzu Tai, James Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C. Christianson, N. Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E. Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Udo Oppermann

Summary: Multiple myeloma (MM) is a plasma cell malignancy associated with aberrant immunoglobulin production and proteotoxic stress. In this study, we identified glutamyl-prolyl-tRNA synthetase (GluProRS) as a potential therapeutic target. By developing a novel inhibitor called NCP26, we demonstrated its significant anti-tumour activity in various in vitro and in vivo systems, overcoming metabolic adaptation observed with other inhibitors. Our findings suggest a complex pro-apoptotic response beyond the integrated stress response, involving downregulated proline-rich motif-containing proteins as downstream effectors and establishing a novel determinant in MM pathobiology.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Hematology

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide- dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2 non-inferiority trial

Kwee Yong, William Wilson, Ruth M. de Tute, Marquita Camilleri, Karthik Ramasamy, Matthew Streetly, Jonathan Sive, Ceri A. Bygrave, Reuben Benjamin, Michael Chapman, Selina J. Chavda, Elizabeth H. Phillips, Maria del Mar Cuadrado, Gavin Pang, Richard Jenner, Tushhar Dadaga, Sumaiya Kamora, James Cavenagh, Laura Clifton-Hadley, Roger G. Owen, Rakesh Popat

Summary: This study aimed to evaluate the efficacy difference between a CAR-T decision-making strategy that does not require autologous HSCT and standard treatment. The results showed that the CAR-T decision-making strategy was not inferior in terms of progression-free survival compared to standard treatment, but further research is still needed.

LANCET HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers

Gaurav Agarwal, Guido Nador, Sherin Varghese, Hiwot Getu, Charlotte Palmer, Edmund Watson, Claudio Pereira, Germana Sallemi, Karen Partington, Neel Patel, Rajkumar Soundarajan, Rebecca Mills, Richard Brouwer, Marina Maritati, Aarti Shah, Delia Peppercorn, Udo Oppermann, Claire M. Edwards, Christopher T. Rodgers, Muhammad Kassim Javaid, Sarah Gooding, Karthik Ramasamy

Summary: This study explores the value of novel serum bone turnover and plasma cell burden markers and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) in patients with multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), and smoldering MM (SMM). The results show potential correlations between serum DKK1 and BCMA with tumor burden, and serum sclerostin with bone mineral density. In addition, DW-MRI is validated for longitudinal assessment of tumor volume. The findings highlight the importance of further exploration and validation of these biomarkers in larger cohorts to improve clinical management of plasma cell dyscrasias.

CANCERS (2023)

Add to Collection

Article Oncology

Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics

Hugh Kikuchi, Eunice Amofa, Maeve Mcenery, Steve Arthur Schey, Karthik Ramasamy, Farzin Farzaneh, Yolanda Calle

Summary: Osteoclast activation leads to drug resistance and bone destruction in multiple myeloma patients. We have identified GDC-0941 as a drug candidate that can enhance the efficacy of existing therapies and reduce bone resorption. This study provides new insights into the treatment of multiple myeloma patients with active bone disease.

CANCERS (2023)

Add to Collection

Editorial Material Hematology

Flicking the switch in myeloma MRD

Edmund Watson, Karthik Ramasamy

Summary: In their study, Paiva et al1 demonstrate that serial monitoring of measurable residual disease (MRD) during maintenance treatment of multiple myeloma (MM) can capture the dynamic conversion between negative (MRD-) and positive (MRD+) states, and can robustly predict progression-free survival (PFS). They also show the feasibility of longer-term MRD monitoring, providing a rationale for trials investigating intervention before frank relapse.

BLOOD (2023)

Add to Collection

Correction Oncology

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma (vol 13, 12, 2023)

Keiji Kurata, Anna James-Bott, Mark A. Tye, Leona Yamamoto, Mehmet K. Samur, Yu-Tzu Tai, James Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C. Christianson, N. Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E. Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Udo Oppermann

BLOOD CANCER JOURNAL (2023)

Add to Collection

Editorial Material Oncology

Editorial: T-cell directed therapies in multiple myeloma

Joshua Richter, Larry D. Anderson Jr, Karthik Ramasamy, Adriana Rossi

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

P. G. Richardson, S. Trudel, R. Popat, M- Mateos, A. J. Vangsted, K. Ramasamy, J. Martinez-Lopez, H. Quach, R. Z. Orlowski, M. Arnao, S. Lonial, C. Karanes, C. Pawlyn, K. Kim, A. Oriol, J. G. Berdeja, P. Rodriguez Otero, I Casas-Aviles, A. Spirli, J. Poon, S. Li, J. Gong, L. Wong, M. Lamba, D. W. Pierce, M. Amatangelo, T. Peluso, P. Maciag, J. Katz, Michael Pourdehnad, Nizar J. Bahlis

Summary: In this study, patients with relapsed and refractory multiple myeloma received oral mezigdomide in combination with dexamethasone. The combination therapy showed promising efficacy in heavily pretreated patients with multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Cell Biology

Multiple myeloma and its treatment contribute to increased platelet reactivity

Joanne L. Mitchell, Dalia Khan, Rekha H. Rana, Neline Kriek, Amanda J. Unsworth, Tanya Sage, Alexander P. Bye, Michael Laffan, Susan Shapiro, Anjan Thakurta, Henri Grech, Karthik Ramasamy, Jonathan M. Gibbins

Summary: This pilot study demonstrated that patients with MGUS, SM and MM have increased platelet reactivity and prothrombotic potential, which is further exacerbated by treatment with Lenalidomide.

PLATELETS (2023)

Add to Collection

Review Oncology

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina Patel, Karthik Ramasamy, Maria-Victoria Mateos

Summary: Bispecific antibodies (BsAbs) are a new class of immunotherapeutic agents for multiple myeloma (MM) and carry a distinct adverse event (AE) profile, which requires guidance on infection monitoring, prophylaxis, and treatment. This review provides consensus recommendations from global experts and covers the management of infection risk factors and the monitoring, prophylaxis, and treatment of bacterial, viral, and fungal infections, including emerging infections like COVID-19. The recommendations are graded based on available data and include herpes simplex and varicella zoster virus prophylaxis, hepatitis B virus reactivation risk screening, monthly intravenous immunoglobulin treatment for immunoparesis, use of colony-stimulating factors in patients with Grade 3 neutropenia, universal pneumocystis jirovecii pneumonia prophylaxis, and no routine anti-fungal prophylaxis.

BLOOD CANCER JOURNAL (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.